What Aopia Biosciences does

Aopia Biosciences, Inc. is a privately-held biotechnology company founded in 2019 and headquartered in Pleasanton, California, that develops and commercializes tools for extracellular vesicle (EV) isolation, purification, and analysis. The company's core technology is the proprietary VanoFlow® filtration cassette, which underpins the NanoEX™ automated bio-nanoparticle isolation platform — a system that the company reports achieves greater than 99.9% free protein removal and greater than 80% EV recovery while processing 5 mL to 2 L of input material in hours with under five minutes of hands-on time. The platform is sold as a series of cassettes (EXO-01 through EXO-60) in both reusable and single-use formats, and is complemented by MSCPure™, a reagent that improves EV purity from mesenchymal stem cell cultures.

Aopia sells its instruments, consumables, and reagents directly to academic and government EV researchers (its primary segment) and to biotechnology and pharmaceutical companies working on EV-based therapeutics, biomarkers, and cell therapy manufacturing QC (its secondary segment). Distribution is augmented by an international distributor network, and the company has built visibility through the ISEV conference community and the 2023 MedTech BioTools Innovator Capstone event. Pricing is not publicly disclosed and customers engage through direct sales inquiry.

Beyond products, Aopia offers research services including NanoEX-based isolation, tangential flow filtration, size exclusion chromatography, nanoparticle tracking analysis, fluorescent EV characterization, biomarker analysis, and cell culture services spanning more than 200 cell lines at scales up to 10 L. Revenue, funding, and customer counts are not publicly disclosed, and the company appears to be at an early commercialization stage with a headcount in the 1-10 range, led by CEO Nan Su. The economic model combines instrument placement with recurring consumable and reagent revenue and a services line, targeting the workflow needs of academic core facilities and translational biotech programs.

Name

Aopia Biosciences

Legal name

Aopia Biosciences, Inc.

Website

https://aopiabio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Aopia Biosciences is a Pleasanton, California-based biotechnology company that develops the NanoEX™ automated platform and proprietary VanoFlow® filtration cassettes for high-purity extracellular vesicle isolation, selling instruments, consumables, and research services to academic researchers and biotech/pharma customers in the EV therapeutics and diagnostics field.

Ownership category

akta.pro rank

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Research Instruments and Consumables: Sale of NanoEX automated isolation platforms and VanoFlow filtration cassettes. The VanoFlow cassettes come in reusable and single-use variants, providing recurring consumable revenue opportunities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Aopia Biosciences develops and sells the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassette technology to isolate and purify extracellular vesicles (EVs). The company also offers MSCPure™ reagent for MSC-derived EV purity improvement and provides research services covering EV isolation, EV analysis, and cell culture for biomedical research, diagnostics, and therapeutic applications.

Product overview

Aopia Biosciences offers a portfolio of products and services for extracellular vesicle (EV) isolation and analysis. The core product is the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassettes to achieve >99.9% free protein removal. This platform is complemented by MSCPure™, a reagent that improves EV purity from MSC (mesenchymal stem cell) cultures. The company also provides research services including EV isolation (NanoEX, TFF, SEC), EV analysis (NTA, fluorescent characterization, biomarker analysis), and cell services (200+ cell lines, culture up to 10L scale, large-scale EV production).

Differentiator

Problem solved

Functional benefit

Brands

• NanoEX™: Automated bio-nanoparticle isolation platform for EV isolation with VanoFlow® technology. Features include fully automated processing, >80% recovery rate, and >99.9% free protein removal.
• MSCPure™
• VanoFlow®

Products and services

• NanoEX™ Automated Bio-nanoparticle Isolation Platform Automated bio-nanoparticle isolation instrument that provides fully automated processing with >80% EV recovery, >99.9% free protein removal, and the ability to process up to 2L of materials in hours with less than 5 minutes hands-on time; for academic researchers, biotech, and pharma customers conducting EV and exosome research.
• VanoFlow® EV Isolation Cassettes Filtration cassettes (VanoFlow-EXO-01, EXO-10, EXO-20, EXO-40, EXO-60) used with the NanoEX platform for EV isolation, featuring fully enclosed processing, external pressure sensing, no cleaning requirement, and elimination of cross-contamination; available in reusable and single-use variants for processing volumes from 10mL to 2L.
• MSCPure™ Reagent Reagent solution that improves MSC-derived EV purity by preventing protein aggregation and facilitating removal of large protein complexes from mesenchymal stem cell (MSC) conditioned culture media; for researchers working with MSC-derived EVs.
• EV Isolation Services Research services using NanoEX-based isolation, Tangential Flow Filtration (TFF), and Size Exclusion Chromatography (SEC) to isolate extracellular vesicles on behalf of academic and biotech customers.
• EV Analysis Services Analysis services including Nanoparticle Tracking Analysis (NTA), fluorescent EV characterization, and biomarker analysis for extracellular vesicle characterization.
• Cell Services Cell culture services offering access to over 200 cancer and normal cell lines, cell culture up to 10L scale, over-expression services, and large-scale EV production from cell lines.

Quantifiable outcome

• >99.9% free protein removal
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• International Society for Extracellular Vesicles (ISEV)coreStrategic or Co-development PartnerAopia Biosciences has a strong relationship with ISEV, launching their NanoEX product at the 2024 ISEV conference and presenting at the ISEVxTech Summit. This partnership provides access to the key opinion leaders and researchers in the EV field.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• RoosterBio: Supplies mesenchymal stem cell (MSC) working cell banks and MSC-derived EV products. Closely comparable to Aopia in the MSC-derived EV space, where Aopia's MSCPure reagent addresses similar MSC EV purity pain points.
• System Biosciences (SBI): Specialist in exosome research tools, including ExoQuick precipitation kits and engineered EV products. Direct competitor in the EV isolation reagent and workflow category that Aopia's MSCPure and NanoEX target.
• Miltenyi Biotec: Provides magnetic-bead-based EV isolation kits and instrumentation for cell and EV separation. Closely comparable to Aopia in selling automated, higher-purity EV isolation workflows to academic and translational research customers.
• Exosomics (now part of Lonza): Specialized in exosome/EV-based liquid biopsy diagnostics and isolation technologies. Direct peer in EV isolation product development, with a focus on clinical diagnostic applications versus Aopia's research and process-development emphasis.

Broad incumbents

• Bio-Techne: Offers EV-related research reagents, including the ExoCap and ExoQuick product lines for exosome isolation and analysis. Overlaps with Aopia's MSCPure reagent and EV analysis services within a broader reagents and proteomics portfolio.
• Lonza Group: Global CDMO with growing exosome/EV manufacturing capabilities, including cell-culture and purification services for therapeutic-grade EVs. Comparable to Aopia's cell and EV production services offering, but at commercial manufacturing scale.
• Thermo Fisher Scientific: Global life-science tools leader offering EV isolation kits, ultracentrifugation equipment, and tangential flow filtration systems. Competes with Aopia's NanoEX platform across the academic and pharma EV research workflow as part of a much broader product portfolio.
• QIAGEN: Provides exosome/EV isolation kits (e.g., exoRNeasy) and downstream nucleic acid analysis solutions. Competes with Aopia across the EV isolation workflow, with stronger downstream molecular biology attach.
• Beckman Coulter Life Sciences: Major manufacturer of ultracentrifuges and rotors widely used for EV isolation. Represents the incumbent method that NanoEX positions against, with a deep installed base in academic and biopharma research labs.

Emerging players

• EVOX Therapeutics: Developer of engineered extracellular vesicle therapeutics. Comparable to Aopia in targeting the EV therapeutics opportunity, but operating as a therapeutic developer rather than a tool provider; signals the demand profile Aopia is positioning to serve.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aopia-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aopia Biosciences